BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) insider Thomas R. Staab II sold 11,750 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $7.81, for a total transaction of $91,767.50. Following the completion of the sale, the insider now directly owns 137,176 shares in the company, valued at approximately $1,071,344.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
BCRX stock traded down $0.25 during midday trading on Friday, hitting $7.32. The stock had a trading volume of 38,685 shares, compared to its average volume of 879,568. The firm has a market cap of $814.09 million, a price-to-earnings ratio of -7.58 and a beta of 1.71. The company has a quick ratio of 1.76, a current ratio of 1.77 and a debt-to-equity ratio of 2.38. BioCryst Pharmaceuticals, Inc. has a 1-year low of $5.34 and a 1-year high of $9.95.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). The business had revenue of $5.89 million for the quarter, compared to analyst estimates of $2.92 million. BioCryst Pharmaceuticals had a negative net margin of 472.12% and a negative return on equity of 223.34%. Research analysts expect that BioCryst Pharmaceuticals, Inc. will post -1.2 earnings per share for the current year.
Several brokerages recently weighed in on BCRX. Zacks Investment Research raised shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 2nd. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $6.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, April 2nd. Finally, BidaskClub lowered shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 28th. Five equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. BioCryst Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $12.06.
COPYRIGHT VIOLATION WARNING: This report was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/17/biocryst-pharmaceuticals-inc-bcrx-insider-sells-91767-50-in-stock.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Featured Story: What are popular range trading strategies?
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.